SPY311.36-0.82 -0.26%
DIA263.33+0.16 0.06%
IXIC9,615.81-67.10 -0.69%
News
BGNE
--
0.00%
--
SVB Leerink Maintains Outperform on BeiGene, Raises Price Target to $210
SVB Leerink maintains BeiGene (NASDAQ:BGNE) with a Outperform and raises the price target from $207 to $210.
Benzinga · 1d ago
BeiGene Announces the Approval of BRUKINSA (Zanubrutinib) in China for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma and Relapsed/Refractory Mantle Cell Lymphoma
GlobeNewswire · 1d ago
BeiGene's zanubrutinib OK'd in China for blood cancers
Seeking Alpha - Article · 1d ago
BeiGene Announces Approval Of BRUKINSA In China For Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma And Relapsed/Refractory Mantle Cell Lymphoma
Benzinga · 1d ago
BeiGene Presents Phase 3 Data on Tislelizumab Combined with Chemotherapy for the Treatment of Patients with Advanced Squamous Non-Small Cell Lung Cancer at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program
GlobeNewswire · 6d ago
BeiGene Presents Updated Head to Head Results from Phase 3 Trial of Zanubrutinib vs. Ibrutinib in Patients with Waldenströms Macroglobulinemia at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program
GlobeNewswire · 6d ago
10 Biggest Price Target Changes For Thursday
KeyBanc boosted Autodesk, Inc. (NASDAQ: ADSK) price target from $210 to $223. Autodesk closed at $199.81 on Wednesday.
Benzinga · 05/28 12:24
Morgan Stanley Maintains Overweight on BeiGene, Raises Price Target to $190
Morgan Stanley maintains BeiGene (NASDAQ:BGNE) with a Overweight and raises the price target from $184 to $190.
Benzinga · 05/28 12:03
BeiGene to Host Investor Conference Call and Webcast to Discuss Clinical Study Results Presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program
GlobeNewswire · 05/26 21:05
Chi-Med, BeiGene Join Forces For Solid Cancer Tumor Treatment
Hutchison China MediTech (HCM) and BeiGene (BGNE) have now entered into a clinical collaboration agreement for the treatment of various solid tumor cancers.The collaboration will evaluate the safety, tolerability and efficacy of two of Chi-Med’s drug candidate
SmarterAnalyst · 05/26 08:04
Chi-Med and Beigene collaborate to evaluate cancer candidates
Seeking Alpha - Article · 05/26 07:18
Chi-Med and BeiGene Enter into Clinical Collaboration to Evaluate Combinations of Surufatinib and Fruquintinib with Tislelizumab
GlobeNewswire · 05/26 07:00
BeiGene inks distribution deal for Brukinsa in Israel
BeiGene (NASDAQ:BGNE) and Medison Pharma Ltd., a global commercial partner for biotech and pharma companies, announced an exclusive distribution agreement
seekingalpha · 05/21 16:19
BeiGene and Medison Pharma Announce Exclusive Distribution Agreement and Acceptance of New Drug Application for BTK Inhibitor BRUKINSA (zanubrutinib) in Israel
GlobeNewswire · 05/21 12:00
BeiGene to Present at the Bernstein 36th Annual Strategic Decisions Conference
GlobeNewswire · 05/20 12:00
BeiGene Announces Clinical and Preclinical Data to Be Presented at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II
GlobeNewswire · 05/15 12:00
Growth Stocks Like Amazon And Tesla Share These Key Metrics: Advisor
Investor's Business Daily · 05/14 22:45
BeiGene Announces Clinical and Non-Clinical Data on BRUKINSA (Zanubrutinib) and Tislelizumab to Be Presented at the 25th European Hematology Association (EHA) Virtual Congress
GlobeNewswire · 05/14 14:00
BeiGene To Present Clinical, Non-Clinical Data On BRUKINSA, Tislelizumab At European Hematology Association Congress Jun. 11-14
BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160)), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today
Benzinga · 05/14 13:15
BeiGene EPADS beats by $0.36, beats on revenue
BeiGene (NASDAQ:BGNE): Q1 GAAP EPADS of -$4.70 beats by $0.36. Revenue of $52.06M (-33.1% Y/Y) beats by $3.56M. Press Release
seekingalpha · 05/12 01:45